Brief: Lantern Pharma Reports Fourth Quarter And Fiscal Year 2022 Financial Results And Operational Highlights
20/03/2023 20:02
March 20 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA REPORTS FOURTH QUARTER AND FISCAL YEAR 2022
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* $55.2 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE
SECURITIES AS OF DECEMBER 31, 2022
* LANTERN HAS A CASH RUNWAY INTO 2025.
* QTRLY LOSS PER SHARE $0.31
* Q4 EARNINGS PER SHARE VIEW $-0.47 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw10TVfka
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments